Viral hemorrhagic fever

This study looks at whether a booster dose of the Ebola vaccine (ERVEBO) can strengthen the immune system of people who have already survived Ebola. Researchers will compare their response to that of healthy people who have never had the virus. The goal is to see if the booster p…

This study was designed to check how long the Ebola vaccine (ERVEBO) protects people who might be exposed at work, like lab workers or healthcare staff. It also planned to see if a booster shot could extend that protection. However, the trial was withdrawn before enrolling any pa…

This early-stage trial is testing a new vaccine called LASSARAB, designed to protect against Lassa fever, a serious viral illness. The vaccine uses a modified rabies virus to deliver the Lassa antigen and includes an adjuvant to boost the immune response. 55 healthy adults will r…

This study tests an experimental vaccine against Sudan ebolavirus in 200 healthy adults aged 18 to 70. The vaccine uses a harmless chimpanzee virus to deliver protection. Researchers will check for side effects and measure immune responses 29 days after vaccination. The goal is t…

This study tests an experimental vaccine against Marburg virus, a rare but severe disease. About 200 healthy adults will receive either the vaccine or a placebo to check for side effects and measure immune responses. The goal is to see if the vaccine is safe and prompts the body …

This Phase 2 trial tests a new vaccine called ChAdOx1 RVF against Rift Valley fever in 240 healthy adults in Kenya. Participants receive either one or two doses of the vaccine or a rabies vaccine as a control. Researchers will check if the vaccine triggers a strong immune respons…

This Phase 2 trial tests a new vaccine called MVA-BN-WEV to prevent two types of equine encephalitis (Eastern and Venezuelan), which are rare but serious brain infections spread by mosquitoes. The study involves 411 healthy adults aged 18-50 and aims to find the best dose and dos…

This study tests a new oral antiviral drug, ARN-75039, for treating Lassa fever, a serious viral illness common in West Africa. About 135 hospitalized adults will receive either a high or low dose of the new drug or the standard IV treatment, ribavirin, for 10 days. The goal is t…

This study looks at whether a special team of doctors and nurses can treat adults with suspected infections at home, instead of sending them to the hospital. About 500 people will be randomly assigned to either standard hospital care or home-based care from a mobile response team…

This study tests whether anakinra, an anti-inflammatory drug, can help people with severe dengue who have dangerously high inflammation. About 160 adults and children will receive either anakinra or a placebo for four days. The goal is to see if anakinra reduces organ failure and…

This early-stage trial is testing the safety of a new drug combination called IDB-011 in 40 healthy adults. The goal is to see if it is safe and how the body processes it, as a first step toward possibly preventing Rift Valley Fever, a viral disease spread by mosquitoes. Particip…

This study aimed to test whether the drug obeldesivir could safely prevent filovirus diseases like Ebola in people who had been exposed. It was designed for adults with known or suspected high-risk contact within the past 21 days. However, the study was withdrawn before enrolling…

This study looks at how the immune system of patients in the intensive care unit (ICU) responds to severe infections caused by viruses or bacteria. Researchers will take extra blood samples from 38 adults to analyze immature granulocytes, a type of immune cell. The goal is to see…

This study aimed to see if a computer could learn to predict how long a patient would stay in a home hospital program. Researchers planned to use data from past patients to train the computer. However, the study was withdrawn before any patients were enrolled, so no results are a…

This study gives 30 healthy adults a single dose of the approved Ebola vaccine (Ervebo) and tracks their immune responses over time using blood, lymph node, and bone marrow samples. The goal is to understand how long the body 'remembers' the vaccine, which could guide future boos…

This study looks at immune cells from people with autoimmune diseases (like lupus), people with infections, and healthy volunteers. Researchers want to understand how these cells differ and what makes them attack the body in autoimmune conditions. The study involves blood and bon…